NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,726,148 | -38.4% | 89,810 | -18.6% | 0.01% | -28.6% |
| Q2 2023 | $2,804,436 | -86.1% | 110,324 | -80.3% | 0.01% | -86.3% |
| Q1 2023 | $20,208,501 | -3.0% | 559,018 | +6.2% | 0.05% | -12.1% |
| Q4 2022 | $20,838,629 | -46.3% | 526,228 | -36.8% | 0.06% | -49.1% |
| Q3 2022 | $38,815,000 | -18.1% | 832,930 | -23.0% | 0.11% | -11.6% |
| Q2 2022 | $47,415,000 | +139.1% | 1,081,801 | +294.6% | 0.13% | +186.7% |
| Q1 2022 | $19,827,000 | +589.9% | 274,123 | +673.4% | 0.04% | +800.0% |
| Q4 2021 | $2,874,000 | +937.5% | 35,446 | +1683.9% | 0.01% | +400.0% |
| Q1 2021 | $277,000 | -82.8% | 1,987 | -78.7% | 0.00% | -66.7% |
| Q4 2020 | $1,612,000 | +161100.0% | 9,313 | +465550.0% | 0.00% | – |
| Q2 2020 | $1,000 | -98.4% | 2 | -99.7% | 0.00% | – |
| Q1 2020 | $64,000 | -99.4% | 639 | -99.3% | 0.00% | -100.0% |
| Q4 2019 | $10,870,000 | +186.5% | 92,480 | +109.6% | 0.02% | +166.7% |
| Q3 2019 | $3,794,000 | -77.2% | 44,131 | -89.7% | 0.01% | -80.0% |
| Q4 2018 | $16,673,000 | -40.2% | 428,721 | -12.3% | 0.04% | -30.8% |
| Q3 2018 | $27,879,000 | +13.0% | 489,108 | +58.2% | 0.06% | -9.7% |
| Q2 2018 | $24,682,000 | -1.0% | 309,100 | +7.4% | 0.07% | 0.0% |
| Q1 2018 | $24,935,000 | +25.5% | 287,700 | 0.0% | 0.07% | +28.6% |
| Q4 2017 | $19,863,000 | -24.0% | 287,700 | 0.0% | 0.06% | -25.3% |
| Q3 2017 | $26,146,000 | +22.1% | 287,700 | 0.0% | 0.08% | +21.0% |
| Q2 2017 | $21,414,000 | -27.9% | 287,700 | -9.3% | 0.06% | -27.1% |
| Q1 2017 | $29,711,000 | +29.0% | 317,085 | 0.0% | 0.08% | +23.2% |
| Q4 2016 | $23,039,000 | -27.2% | 317,085 | +4.6% | 0.07% | -24.2% |
| Q3 2016 | $31,660,000 | +41.4% | 303,285 | -0.1% | 0.09% | +40.0% |
| Q2 2016 | $22,394,000 | +48.0% | 303,608 | +12.9% | 0.06% | +38.3% |
| Q1 2016 | $15,128,000 | +533.8% | 268,900 | +440.0% | 0.05% | +571.4% |
| Q1 2015 | $2,387,000 | -9.9% | 49,800 | -27.3% | 0.01% | -12.5% |
| Q4 2014 | $2,649,000 | – | 68,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |